NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

June 2010 Marketed Drug Updates and Additions

Brand Name

Generic Name

Other Designation

Abraxane

Nanoparticle albumin-bound (nab) paclitaxel, paclitaxel albumin bound (PAB)

ABI-007

Folotyn

Pralatrexate

PDX

 

Oxaliplatin

 

Nexavar

Sorafenib tosylate

BAY 43-9006

Revlimid (formerly Revimid), Lenalidomide-Celgene Europe

Lenalidomide

CDC501, CDC-501, CDC-5013, CC5013, CC-5013

Eloxatin, Eloxatine, Elplat (Japan)

Oxaliplatin (L-OHP)

1670RB, RP 54780

Tasigna

Nilotinib

AMN107, AMN-107

Sutent

Sunitinib malate

SU011248, SU11248, SU-11248

Jevtana

Cabazitaxel

XRP6258, XRP 6258 (formerly RPR116258, RPR116258A, 116258)

Mylotarg

Gemtuzumab ozogamicin

CMA-676, CDP771

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM